Effect of Dash Diet and Acupuncture on Hypertention in Postmenopausal Women

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06015919

Enrollment

Registered

2023-08-29

Start date

2022-12-05

Completion date

2023-08-20

Last updated

2023-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal Disorder

Brief summary

A study of effect of dash diet and acupuncture on hypertension in postmenopausal women

Detailed description

45 of post menopausal women divided into three groups A,B,C * Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs. * Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs. * Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs.

Interventions

BEHAVIORALdash diet

* Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs. * Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs. * Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs.

DEVICEAcupuncture

acupuncture

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

dash diet and acupuncture on post menopausal hypertention

Eligibility

Sex/Gender

FEMALE

Age

50 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Their body mass index will be ranged from 25 -29.9 kg/m2 * All patients will be medically stable when attending the study. * The DASH eating plan of 1800 kcal per day will be used in the study.

Exclusion criteria

* Auditory and visual problems. * Chronic renal failure. * Myocardial infarction or arrythmias with heart failure.

Design outcomes

Primary

Measure	Time frame	Description
blood pressure	3 months	it will be measured by sphygmomanometer pre and post treatment

Secondary

Measure	Time frame	Description
sodium and potassium levels	3 months	it will be measured by blood analysis pre and post treatment

Other

Measure	Time frame	Description
assessment of quality of life	3 months	it will be measured by sf 36 questionnaire pre and post treatment

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026